Insights On Upstream Manufacturing
-
Flexible Automation For Bioprocess Development And Quality Control
11/6/2026
Flexible lab automation can standardize experimentation across upstream process engineering and downstream quality control, while staying adaptable as process requirements shift.
-
Expanding The Transposase Toolkit For Cell Line Engineering
11/6/2026
Combining distinct transposase systems in one cell line opens engineering options beyond single-system insertion, including control over glycosylation, enzymatic function, and more.
-
Rethinking Expression To Accelerate Antibody Discovery
11/5/2026
Expression often limits high-throughput antibody discovery because functional screening needs soluble, correctly folded protein. Explore how moving expression into screening changes which candidates get tested.
-
Exciting Advances In Cell Line Development
11/5/2026
In this segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” panelists Ted Peters, Ph.D., and Ronan O’Kennedy, Ph.D., discuss the trends or advancements that excite them the most, which include a deeper understanding of CHO cell biology and the industry-wide push towards continuous manufacturing.
-
When To Shift To A Master Cell Bank
11/5/2026
In this segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” panelists Ted Peters, Ph.D., and Ronan O’Kennedy, Ph.D., answer audience questions pertaining to master cell banking (MCB) and technology transfer.
-
Clone Selection And CMC Documentation
11/5/2026
This closing segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” focuses on clone selection and the regulatory importance of demonstrating clonality in cell line development (CLD). Panelists Ted Peters, Ph.D., and Ronan O’Kennedy, Ph.D., also share their thoughts on Operation Trial Blazer.
-
Properly Documenting Early Cell Line Development
11/5/2026
In this segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” panelists Ted Peters, Ph.D., and Ronan O’Kennedy, Ph.D., agree that documentation (or rather, failing to document) is the most common issue they’ve encountered teams make in cell line development (CLD). They both believe teams should spend more time correctly documenting early CLD and understanding regulatory requirements ahead of IND submission.
-
Cell Line Platform Selection
11/5/2026
In this segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” panelists Ted Peters, Ph.D., and Ronan O’Kennedy, Ph.D., explore the nuances and considerations surrounding cell line selection, as well as discuss when it’s appropriate to move from transient systems into stable GMP cell lines.
-
Ensuring Stability In Cell Lines
11/5/2026
In this segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” panelists Ted Peters, Ph.D., and Ronan O’Kennedy, Ph.D., discuss the importance of stability in cell lines and how our understanding of this has changed over time.
-
Overlooked Aspects Of Cell Line Development
11/5/2026
This opening segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” features panelists Ted Peters, Ph.D., head of cell line development at Immunome, and Ronan O’Kennedy, Ph.D., from ROK Bioconsulting. Peters and O’Kennedy begin by talking about the areas of cell line development they feel are often overlooked, including the alignment of early-stage work with later-stage work.